• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma.凋亡信号分子作为头颈部鳞状细胞癌的治疗靶点。
Laryngoscope. 2020 Nov;130(11):2643-2649. doi: 10.1002/lary.28441. Epub 2020 Jan 2.
2
Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.芬维 A 联合 ABT-263 通过诱导 NOXA 促进头颈部鳞状细胞癌凋亡。
PLoS One. 2019 Jul 5;14(7):e0219398. doi: 10.1371/journal.pone.0219398. eCollection 2019.
3
Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.顺铂诱导头颈部肿瘤细胞衰老后，通过衰老细胞清除剂进行清除。
Mol Pharmacol. 2022 Mar;101(3):168-180. doi: 10.1124/molpharm.121.000354. Epub 2021 Dec 14.
4
Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.帕博西尼使人乳头瘤病毒阴性的头颈部鳞状细胞癌对衰老细胞清除剂纳维托昔单抗敏感。
Mol Cancer Res. 2021 May;19(5):862-873. doi: 10.1158/1541-7786.MCR-20-0915. Epub 2021 Jan 25.
5
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.ABT-737通过Noxa介导的途径与化疗协同作用，以杀死头颈部鳞状细胞癌细胞。
Mol Pharmacol. 2009 May;75(5):1231-9. doi: 10.1124/mol.108.052969. Epub 2009 Feb 25.
6
Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.评估 BH3 模拟物联合放疗治疗头颈部鳞状细胞癌。
Biomed Pharmacother. 2024 Jun;175:116719. doi: 10.1016/j.biopha.2024.116719. Epub 2024 May 15.
7
Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.顺铂诱导的非小细胞肺癌细胞凋亡依赖于Bax和Bak诱导途径，并在p53野生型和突变型细胞中被BH3模拟物ABT-263协同激活。
Biochem Biophys Res Commun. 2016 Apr 29;473(2):490-6. doi: 10.1016/j.bbrc.2016.03.053. Epub 2016 Mar 18.
8
Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.SF3B1抑制剂对头颈部癌细胞中HPV16 E6和MCL1的调控
Sci Rep. 2014 Aug 20;4:6098. doi: 10.1038/srep06098.
9
The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.蛋白酶体抑制剂 MG132 通过稳定人头颈鳞状细胞癌细胞中的 tBid 和 Bik 增强 TRAIL 受体激动剂诱导的细胞凋亡。
Exp Cell Res. 2012 Aug 1;318(13):1564-76. doi: 10.1016/j.yexcr.2012.04.003. Epub 2012 Apr 10.
10
Assessment of the methylene blue mediated photodynamic therapy on and genes expression at mRNA level and apoptosis of head and neck squamous cell carcinoma cell line.评估亚甲蓝介导的光动力疗法对头颈部鳞状细胞癌细胞系 和 基因表达及细胞凋亡的影响。
Folia Med (Plovdiv). 2022 Apr 30;64(2):221-228. doi: 10.3897/folmed.64.e60825.

引用本文的文献

1
Novel Predictive Biomarkers in the Head and Neck Squamous Cell Carcinoma (HNSCC).头颈部鳞状细胞癌（HNSCC）中的新型预测生物标志物
J Clin Med. 2024 Oct 2;13(19):5876. doi: 10.3390/jcm13195876.
2
Panoramic analysis of cell death patterns reveals prognostic and immune profiles of head and neck squamous cell carcinoma.细胞死亡模式的全景分析揭示了头颈部鳞状细胞癌的预后和免疫特征。
Am J Cancer Res. 2024 May 15;14(5):2584-2607. doi: 10.62347/PMDA6193. eCollection 2024.
3
ALKBH5 promotes hypopharyngeal squamous cell carcinoma apoptosis by targeting TLR2 in a YTHDF1/IGF2BP2-mediated manner.ALKBH5通过YTHDF1/IGF2BP2介导的方式靶向TLR2促进下咽鳞状细胞癌凋亡。
Cell Death Discov. 2023 Aug 23;9(1):308. doi: 10.1038/s41420-023-01589-6.
4
Reinstating apoptosis using putative Bcl-xL natural product inhibitors: Molecular docking and ADMETox profiling investigations.使用假定的Bcl-xL天然产物抑制剂恢复细胞凋亡：分子对接和ADMETox分析研究。
J Taibah Univ Med Sci. 2022 Nov 14;18(3):461-469. doi: 10.1016/j.jtumed.2022.10.014. eCollection 2023 Jun.
5
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma.调节性细胞死亡对头颈部鳞状细胞癌发生发展的影响
Biomark Res. 2023 Jan 5;11(1):2. doi: 10.1186/s40364-022-00433-w.
6
Identification of Molecular Targets and Potential Mechanisms of Yinchen Wuling San Against Head and Neck Squamous Cell Carcinoma by Network Pharmacology and Molecular Docking.基于网络药理学和分子对接技术探讨茵陈五苓散抗头颈部鳞状细胞癌的分子靶点及潜在机制
Front Genet. 2022 Jul 6;13:914646. doi: 10.3389/fgene.2022.914646. eCollection 2022.
7
Prognosis and Characterization of Immune Microenvironment in Head and Neck Squamous Cell Carcinoma through a Pyroptosis-Related Signature.通过焦亡相关特征对头颈部鳞状细胞癌免疫微环境的预后及特征分析
J Oncol. 2022 Apr 6;2022:1539659. doi: 10.1155/2022/1539659. eCollection 2022.
8
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.硼替佐米对蛋白酶体的抑制作用类似于减少头颈部癌细胞的生长，并增加肿瘤浸润免疫细胞。
Sci Rep. 2021 Sep 24;11(1):19051. doi: 10.1038/s41598-021-98450-6.
9
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma.高通量化合物筛选鉴定出 navitoclax 联合辐射治疗 HPV 阴性头颈部鳞状细胞癌的候选疗法。
Sci Rep. 2021 Jul 20;11(1):14755. doi: 10.1038/s41598-021-94259-5.
10
Astragaloside IV and Saponins of Rhizoma Polygonati Cure Cyclophosphamide-Induced Myelosuppression in Lung Adenocarcinoma Down-Regulating miR-142-3p.黄芪甲苷和黄精皂苷通过下调miR-142-3p治疗环磷酰胺诱导的肺腺癌骨髓抑制
Front Oncol. 2021 Apr 20;11:630921. doi: 10.3389/fonc.2021.630921. eCollection 2021.

本文引用的文献

1
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal in Relapsed Mantle Cell Lymphoma.维奈托克联合 S63845 靶向 BCL2 和 MCL1 对复发性套细胞淋巴瘤具有合成致死作用。
Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.
2
Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1.在头颈部鳞状细胞癌中，对BCL家族蛋白进行最佳靶向需要同时抑制BCL-xL和MCL-1。
Oncotarget. 2019 Jan 11;10(4):494-510. doi: 10.18632/oncotarget.26563.
3
In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity.在人乳头瘤病毒阳性的头颈部鳞状细胞癌（HNSCC）细胞中，蛋白酶体抑制剂硼替佐米对p53/p21通路的功能恢复不影响放射敏感性或化学敏感性。
Transl Oncol. 2019 Mar;12(3):417-425. doi: 10.1016/j.tranon.2018.11.013. Epub 2018 Dec 14.
4
ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.ABT-199 通过抑制 Bcl-2 作为治疗鼻咽癌的潜在策略。
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1214-1220. doi: 10.1016/j.bbrc.2018.07.027. Epub 2018 Jul 17.
5
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.硼替佐米的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Feb;58(2):157-168. doi: 10.1007/s40262-018-0679-9.
6
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.针对抗凋亡 BCL-2 家族的差异化成瘾进行癌症治疗。
Nat Commun. 2017 Jul 17;8:16078. doi: 10.1038/ncomms16078.
7
Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma.阿法替尼通过PERK-eIF2α-ATF4轴下调MCL-1表达，并导致头颈部鳞状细胞癌发生凋亡。
Am J Cancer Res. 2016 Aug 1;6(8):1708-19. eCollection 2016.
8
Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.索拉非尼增强ABT - 737诱导的人口腔癌细胞凋亡。
Arch Oral Biol. 2017 Jan;73:1-6. doi: 10.1016/j.archoralbio.2016.08.034. Epub 2016 Aug 31.
9
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
10
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.通过AT-101靶向抗凋亡蛋白Bcl-2以提高放射疗效：来自头颈癌体外和临床药代动力学研究的数据
Radiat Oncol. 2015 Jul 30;10:158. doi: 10.1186/s13014-015-0474-9.

凋亡信号分子作为头颈部鳞状细胞癌的治疗靶点。

Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma.

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.

Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.

出版信息

Laryngoscope. 2020 Nov;130(11):2643-2649. doi: 10.1002/lary.28441. Epub 2020 Jan 2.

DOI:10.1002/lary.28441
PMID:31894587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142150/
Abstract

OBJECTIVES

To evaluate BCL-2 family signaling molecules in head and neck squamous cell carcinoma (HNSCC) and examine the ability of therapeutic agents with variable mechanisms of action to induce apoptosis in HNSCC cells.

METHODS

messenger ribonculeic acid (mRNA) expression of BAK, BAX, B-cell lymphoma (Bcl-2), BCL2 Like 1 (BCL2L1), and MCL1 were measured in The Cancer Genome Atlas (TCGA) head and neck cancer dataset, as well as in a dataset from a cohort at Montefiore Medical Center (MMC). Protein expression was similarly evaluated in a panel of HNSCC cell lines (HN30, HN31, HN5, MDA686LN, UMSCC47). Cell viability and Annexin V assays were used to assess the efficacy and apoptotic potential of a variety of agents (ABT-263 [navitoclax], A-1210477, and bortezomib.

RESULTS

Expression of BAK, BAX, BCL2L1, and MCL1 were each significantly higher than expression of BCL2 in the TCGA and MMC datasets. Protein expression demonstrated the same pattern of expression when examined in HNSCC cell lines. Treatment with combined ABT-263 (navitoclax)/A-1210477 or with bortezomib demonstrated apoptosis responses that approached or exceeded treatment with staurospaurine control.

CONCLUSION

HNSCC cells rely on inhibition of apoptosis via BCL-xL and MCL-1 overexpression, and induction of apoptosis remains a potential therapeutic option as long as strategies overcome redundant anti-apoptotic signals.

LEVEL OF EVIDENCE

NA Laryngoscope, 130:2643-2649, 2020.

摘要

目的

评估头颈部鳞状细胞癌（HNSCC）中 BCL-2 家族信号分子，并研究作用机制不同的治疗药物诱导 HNSCC 细胞凋亡的能力。

方法

在癌症基因组图谱（TCGA）头颈部癌症数据集以及 Montefiore 医疗中心（MMC）队列的数据集中，测量 BAK、BAX、B 细胞淋巴瘤（Bcl-2）、BCL2 样 1（BCL2L1）和 MCL1 的信使核糖核酸（mRNA）表达。在一系列 HNSCC 细胞系（HN30、HN31、HN5、MDA686LN、UMSCC47）中同样评估蛋白表达。细胞活力和 Annexin V 检测用于评估各种药物（ABT-263[navitoclax]、A-1210477 和硼替佐米）的疗效和凋亡潜力。

结果

TCGA 和 MMC 数据集均显示，BAK、BAX、BCL2L1 和 MCL1 的表达均显著高于 BCL2 的表达。在 HNSCC 细胞系中检测到蛋白表达呈现相同的表达模式。联合使用 ABT-263（navitoclax）/A-1210477 或硼替佐米治疗可诱导接近或超过星形孢菌素对照的凋亡反应。

结论

HNSCC 细胞依赖于 BCL-xL 和 MCL-1 的过度表达抑制凋亡，只要诱导凋亡的策略能够克服冗余的抗凋亡信号，诱导凋亡仍然是一种潜在的治疗选择。

证据水平

无 喉科学，130：2643-2649，2020。